Check Cap Ltd (NASDAQ:CHEK) traded up 71.9% on Thursday . The company traded as high as $3.35 and last traded at $2.39, with a volume of 5,375,764 shares changing hands. The stock had previously closed at $1.39.

A number of equities research analysts have recently weighed in on the company. Maxim Group reiterated a “buy” rating on shares of Check Cap in a report on Thursday, May 19th. Zacks Investment Research downgraded Check Cap from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, Chardan Capital lowered their price objective on Check Cap from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, May 20th.

The company has a 50-day moving average price of $1.36 and a 200 day moving average price of $2.23. The company’s market capitalization is $40.24 million.

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.